Genscript Biotech Co. (OTCMKTS:GNNSF) Short Interest Update

Genscript Biotech Co. (OTCMKTS:GNNSF) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 4,198,000 shares, a growth of 71.7% from the July 30th total of 2,444,582 shares. Based on an average daily volume of 3,300 shares, the short-interest ratio is presently 1,272.1 days.

Genscript Biotech Stock Performance

GNNSF stock traded down C$0.15 during midday trading on Monday, hitting C$4.35. The company’s stock had a trading volume of 2,597 shares, compared to its average volume of 4,686. The firm has a 50-day simple moving average of C$2.34 and a 200-day simple moving average of C$1.84. Genscript Biotech has a 52-week low of C$1.30 and a 52-week high of C$5.00.

Genscript Biotech Company Profile

GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.

The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.